Authorizing Cannabis for Medical Purposes

Policy document

POLICY TYPE

LAST REVIEWED 2020-02-29

DATE 2015-02-28

TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE Parliamentary submission
DATE 2014-10-28
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11519

POLICY TYPE Parliamentary submission
DATE 2015-05-14
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-17 An Act to amend the Food and Drugs Act
https://policybase.cma.ca/link/policy11196

POLICY TYPE  Parliamentary submission
DATE  2014-06-11
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE          Parliamentary submission
DATE                2017-08-18
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE: Parliamentary submission
DATE: 2018-04-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE: Policy endorsement
DATE: 2017-05-26
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes

CMA POLICY

Limitations:

The Canadian Medical Association (CMA) recognizes the evolving understanding of the use of cannabis in the treatment of certain conditions. The Association supports the need for further research to better understand the potential benefits and harms of cannabis for these conditions.

The CMA recommends the following:

1. The provision of education and training for healthcare providers on the use of cannabis for medical purposes.
2. The development of guidelines and standards for the safe and effective use of cannabis for medical purposes.
3. The establishment of a regulatory framework to ensure the safe and effective use of cannabis for medical purposes.

The CMA is committed to continuing its involvement in the development and refinement of policies related to the use of cannabis for medical purposes.
CMA Presentation to the Senate Standing Committee on Social Affairs, Science and Technology - Prescription Drugs: Clinical Trials and Approval
https://policybase.cma.ca/link/policy10437

POLICY TYPE: Parliamentary submission
DATE: 2012-05-09
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Response: Health Canada's Medical Marijuana Regulatory Proposal
https://policybase.cma.ca/link/policy10702

POLICY TYPE: Parliamentary submission
DATE: 2013-02-28
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE
Response to consultation

DATE
2017-06-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE
Parliamentary submission

DATE
2017-04-07

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
CMA’s recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the Senate Standing Committee on Social Affairs, Science and Technology

April 7, 2017
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13918

POLICY TYPE
Parliamentary submission

DATE
2018-02-15

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)

https://policybase.cma.ca/link/policy11599

POLICY TYPE: Response to consultation
DATE: 2015-06-08
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the House of Commons Standing Committee on Health: Drug Shortages
https://policybase.cma.ca/link/policy10382

POLICY TYPE  Parliamentary submission
DATE  2012-03-29
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety

https://policybase.cma.ca/link/policy11125

POLICY TYPE  Parliamentary submission
DATE  2014-03-26
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs